Input Submission - Implementation Advice - Proposed Scope -HC0097-000 - SX0849-000 Canada’s Drug Agency is convening an implementation advice panel to advise the drug programs on funding criteria for icatibant for hereditary angioedema (HAE) with normal C1-inhibitor function (HAE nC1-INH), also known as type III HAE. Status message Sorry… This form is closed to new submissions.
Input Submission - Implementation Advice - Proposed Scope -HC0097-000 - SX0849-000 Canada’s Drug Agency is convening an implementation advice panel to advise the drug programs on funding criteria for icatibant for hereditary angioedema (HAE) with normal C1-inhibitor function (HAE nC1-INH), also known as type III HAE. Status message Sorry… This form is closed to new submissions.
